Pfizer announces positive results from Phase 3 study of 20-valent pneumococcal conjugate vaccine
Pfizer plans to submit an sBLA by the end of this year, subject to discussions with U.S. FDA
Pfizer plans to submit an sBLA by the end of this year, subject to discussions with U.S. FDA
This will not only strengthen the country’s overall position in the global vaccine industry but also reduce its reliance on foreign vaccines
Merck’s first microbiology application and training lab in India
Novavax' vaccine is the first protein-based COVID-19 vaccine authorized in the U.S.
Proportion of the eligible population yet to receive a COVID-19 vaccine is comparatively small
Sanofi will begin to ship their vaccines helping to ensure more people will be immunized
Submission seeks approval for the treatment of COVID-19 in both vaccinated and unvaccinated individuals at high risk
105 million 30 µg, 10 µg and 3 µg doses to be delivered into Q4 2022, with an option for the U.S. Government to purchase up to 195 million additional doses
States were also strongly advised to strictly monitor epidemiological profile of admitted COVID patients
The Minister directed officials to continue to focus on surveillance and on Whole Genome Sequencing to scan for any possible mutation and also directed for monitoring hospitalizations due to COVID-19 and SARI/ILI cases
Subscribe To Our Newsletter & Stay Updated